Skip to main content
Download PDF

Quick and effective improvement of leucine enriched dietary supplement on malnutrition in acute stroke patients receiving enteral tube feeding

BMC Emergency Medicine volume 20, Article number: 56 (2020) Cite this article

A Correction to this article was published on 29 December 2020

This article has been updated

Abstract

Background

Malnutrition often occurs in acute stroke patients receiving enteral tube feeding (ETF). Unless malnutrition is improved, their clinical outcome is poor. However, strategies to improve malnutrition in these patients have not been established. Branched-chain amino acids (BCAA) may enhance protein synthesis and attenuate inflammation. Our study aimed to investigate whether a leucine enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs).

Methods

We retrospectively included acute stroke patients who: 1) were admitted between August 2016 and July 2017; 2) underwent ETF for 7 days or longer after admission, and 3) underwent blood examination of Alb, TTR, and CRP on admission, the fifth day and the seventh day. We defined severe malnutrition as severe hypoproteinemia: decrease of TTR to less than 15 mg/dl on the 5th day. In LEBDs and SBDs groups, patients started to receive a dietary supplement containing leucine of 1.44 and 0. 72 g twice a day on the fifth day, respectively. We evaluated Alb (g/dl), TTR (mg/dl), and CRP (mg/dl) on admission, the fifth day, and the seventh day.

Results

Twenty-nine patients met our inclusion criteria:15 in LEBDs and 14 in SBDs. In LEBDs and SBDs groups, the median Alb was 3.5 and 3.3 g/dl, TTR was 12.7 and 10.7 mg/dl, and CRP was 1.02 and 0.673 mg/dl on admission, respectively. In LEBDs, the median Alb and TTR decreased to 2.6 g/dl and 11.9 mg/dl, and CRP increased to 5.337 mg/dl on the fifth day. On the 7th day, TTR increased, and CRP decreased, although Alb did not improve. In SBDs, the median Alb and TTR decreased to 2.6 g/dl and 9.7 mg/dl, and CRP increased to 4.077 mg/dl on the fifth day. On the 7th day, Alb, TTR, and CRP did not improve.

Conclusion

In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed.

Peer Review reports

Background

Malnutrition often occurs in severe acute stroke patients who are unable to take foods orally due to dysphagia or disturbed level of consciousness and who must receive enteral tube feeding (ETF) [1,2,3]. Malnutrition leads to the severity of the general condition and subsequently extended stay in hospital or in-hospital mortality [4,5,6,7]. Malnutrition may contribute to a weakened immune system and causes infection to occur [8]. Acute inflammation associated with infection exacerbates hypoproteinemia, and the clinical outcomes in patients with severe hypoproteinemia are generally poor. If malnutrition occurs in a patient, it should be treated and improved as soon as possible. Inflammation must be attenuated as soon as possible. However, it has not been established on how to improve hypoproteinemia rapidly [9]. Larger volumes of protein intake in the diet do not always lead to rapid improvement of hypoproteinemia and cessation of inflammation due to anabolic resistance in a severe clinical state [10, 11]. Leucine is one of the essential amino acids and one of the branched-chain amino acids (BCAA) [12], and previous studies have reported that leucine enriched BCAA supplement may attenuate inflammation, enhance protein synthesis [13,14,15] and may be useful in recovering muscle mass and strength and in promoting rehabilitation [13, 16,17,18,19]. Our study aimed to investigate whether leucine-enriched BCAA dietary supplement (LEBDs) could quickly increase serum levels of albumin (Alb) or transthyretin (TTR) and quickly decrease high-sensitivity C-reactive protein (CRP) in the development of severe malnutrition within a few days after stroke onset compared to standard BCAA dietary supplement (SBDs).

Methods

For the retrospective observational study, we included acute stroke patients who: 1) were admitted between August 2016 and July 2017, 2) started ETF on the second day and continued to undergo ETF for 7 days or longer after admission, 3) underwent blood examination on admission, the fifth day and the seventh day, and 4) started to receive LEBDs or SBDs to improve severe malnutrition on the fifth day. We defined severe malnutrition as rapid progression of hypoproteinemia: decrease of TTR to less than 15 mg/dl, as TTR is a rapid turnover protein [20]. Patients started to receive LEBDs or SBDs twice a day on the fifth day added to baseline enteral nutrients.

Exclusion criteria

We excluded from our analysis patients who: 1) died due to very severe stroke within 7 days after its onset, 2) could take foods orally on admission, or 3) did not undergo a thorough blood examination.

Target calories

We calculated the target calories for patients according to the Harris-Benedict Equation (HBE) [21].

Enteral nutrients

We started to administer enteral nutrients on the second day of admission. Enteral nutrients (EN) we used to be IMPACT (Nestle Japan Co. Ltd.), PEPTAMEN AF (Nestle Japan Co. Ltd.), MEIN (Meiji Co. Ltd., Japan) or RENALEN MP (Meiji Co. Ltd., Japan). IMPACT includes contents that consist of protein of 14 g (arginine-enhanced), containing leucine of 0.975 g, lipid of 7.0 g, containing middle-chain triglyceride (MCT) of 1.5 g, and carbohydrates of 33.5 g against 250 kcal per 250 ml of one pack. PEPTAMEN AF includes contents that consist of protein of 19 g, containing leucine of 2.03 g and whey peptide, lipid of 13.2 g, containing MCT of 6.7 g, and carbohydrates of 26.4 g against 300 kcal per 200 ml of one pack. MEIN consists of protein of 10 g, containing leucine of 0.96 g and whey peptide, lipid of 5.6 g, containing MCT of 1.2 g, and carbohydrates of 29.8 g, containing palatinose, against 200 kcal per 200 ml of one pack. Renalen MP consists of protein of 14 g, containing leucine of 1.32 g, lipid of 11.2 g, containing MCT of 2.3 g, and carbohydrates of 64.0 g, containing palatinose, against 400 kcal per 250 ml of one pack. Palatinose is a disaccharide that consists of one glucose and one fructose, and it has a low glycemic index. Enteral nutrients except for RENALEN MP were protein-rich nutrients. Leucine enriched BCAA dietary supplement (LEBDs) (Leucine Plus, Nestle, and Ajinomoto, Japan) consists of protein of 8 g, containing 1.44 g of leucine, and sugar of 18.5 g, against 200 kcal per 100 ml of one pack, and standard BCAA dietary supplement (SBDs) (Meibalance Mini, Meiji Co. Ltd., Japan) consists of protein of 7.5 g, containing leucine of 0.72 g and sugar of 29.3 g, against 200 kcal of one pack (Table 1). Protein volume in LEBDs was almost the same as in SBDs.

Table 1 Contents of leucine enriched and standard BCAA dietary supplements
Full size table

Evaluation

We evaluated patient features, TTR, Alb, and high-sensitivity CRP on admission, the fifth day, the 7th day, because previous studies have reported CRP elevation and decrease in Alb or TTR in patients with severe inflammation or severe acute conditions [22,23,24]. Besides, we evaluated Glasgow Coma Scale (GCS) [25], in-hospital clinical outcome, hospitalization days, and serum Cre on admission, the fifth day, the 7th day, because deterioration of renal function was a possible adverse effect of protein-rich EN.

Statistical analysis

Non-normally distributed continuous variables were expressed as the median and interquartile range (IQR). Differences between LEBDs and SBDs were compared using a Fisher’s exact test for categorical variables and a Wilcoxon rank-sum test for non-parametric data. For a comparison of paired variables, we used a Wilcoxon signed-rank test for non-parametric data. We performed a two-sided test for unpaired variables, a one-sided test for paired variables, and considered a probability of less than 0.05 statistically significant. We used the JMP (version 15.1) program to perform the statistical analysis.

Results

During the study period, we treated 800 acute stroke patients in our institution. Among patients who underwent ETF on the second day, the TTR level on the fifth day was less than 15 mg/dl in 29 patients, and the 15 patients started to receive LEBDs and the 14 patients started to receive SBDs on the 5th day. There were no differences in patients’ characteristics between the two groups. Their median age was older than 80 years. In LEBDs and SBDs groups, the median GCS on admission was 9 and 9.5, respectively, and they suffered from impaired consciousness.

In LEBDs and SBDs groups, the median Alb was 3.5 and 3.3 g/dl (ns), TTR was 12.7 and 10.7 mg/dl (ns), and CRP was 1.02 and 0.673 mg/dl (ns) on admission, respectively (Table 2). In LEBDs group, patients received baseline protein intake of 1.2 (g/kg/day) by enteral nutrition (Table 3). However, the median Alb decreased to 2.6 g/dl (p <  0.0001) and the median TTR decreased to 11.9 mg/dl (p <  0.001), and CRP increased to 5.337 mg/dl (p <  0.05) on the fifth day. We added the LEBDs (2.88 g of leucine/400 kcal/200 ml/day) to baseline EN. On the 7th day, TTR increased (p <  0.001) and CRP decreased (p <  0.05) although Alb did not improve (Figs. 1, 2 and 3; left) (Table 4). In SBDs group, patients received baseline protein intake of 1.4 (g/kg/day) by enteral nutrition (Table 3). However, the median Alb decreased to 2.6 g/dl (p <  0.0001) and the median TTR decreased to 9.7 mg/dl (p < 0.05), and the median CRP increased to 4.077 (p < 0.05) on the fifth day. We added the SBDs (1.44 g of leucine/400 kcal/250 ml/day) to baseline EN. On the 7th day, Alb, TTR and CRP did not improve (Figs. 1, 2 and 3; right) (Table 4). The serum TTR level on the 7th day was higher in LEBDs than in SBDs, although there were no differences in TTR on the 5th day between LEBDs and SBDs (Table 2).

Table 2 Patients’ characteristics in Leucine enriched and standard BCAA dietary supplements
Full size table
Table 3 Patients charactreristics in leucine enriched and standard BCAA dietary supplements
Full size table
Fig. 1
figure 1

Serial changes of serum TTR on admission, on the fifth day, and the seventh day. One-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, TTR: transthyretin

Full size image
Fig. 2
figure 2

Serial changes of serum Alb on admission, on the fifth day and the seventh day. As shown, a one-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, Alb: albumin

Full size image
Fig. 3
figure 3

Serial changes of serum CRP on admission, on the fifth day and the seventh day. One-sided Wilcoxon signed-rank test was performed. Left: Leucine enriched BCAA dietary supplement, Right: Standard BCAA dietary supplement, BCAA: branched-chain amino acid, CRP: high-sensitivity C-reactive protein

Full size image
Table 4 Changes of serum markers in leucine enriched and standard BCAA dietary supplements
Full size table

In LEBDs group, the median creatinine (Cre) and estimated glomerular filtration rate (eGFR) on admission were 0.78 (mg/dl), and 56.4 (mL/min/1.73m2), respectively. In 12 of the 15 patients, eGFR was less than 60 (mL/min/1.73 m2). The 12 patients suffered from renal dysfunction on admission (Table 3). In LEBDs group, the median target calorie and real calorie intake by EN was 1328 and 1200 kcal/day, respectively. The calorie status was 90.4% of the plan on the fifth day. We used protein-rich EN except for REANALEN MP in 12 of the 15 patients (Table 3). In SBDs group, their median Cre and eGFR, on admission were 0.70 (mg/dl), and 66.3 (mL/min/1.73 m2). In 5 of the 14 patients, eGFR was less than 60 (mL/min/1.73m2). The 5 patients suffered from renal dysfunction on admission (Table 3). In SBDs group, the median target calorie and real calorie intake by EN was 1248 and 1200 kcal/day, respectively. The calorie status was 96.2% of the plan on the fifth day. We used protein-rich EN except for REANALEN MP in 13 of the 14 patients (Table 3).

Overall renal function did not deteriorate except for two cases in LEBDs group (Table 4). In Case 2 and 4 in LEBDs group, serum Cre level acutely rose on the fifth day, and protein per day by PEPTAMEN AF was reduced from 75.6 to 56.7 g from the fifth day. The LEBDs was added on protein of 56.7 g by PEPTAMEN AF in case 2 and 4, and their Cre level did not deteriorate on the seventh day (Tables 3 and 4).

In LEBDs, 13 (86.7%) of the 15 patients discharged within 17 days, and they were transferred to comprehensive rehabilitation centers after their TTR and CRP were improving. Two of the 15 patients died on the eighth day and the twenty-first day, respectively. Median hospitalization in LEBDs was 12 days. In SBDs, 12 (85.7%) of the 14 patients discharged within 17 days, and they were transferred to comprehensive rehabilitation centers, although neither TTR nor CRP were not improving. One of the 14 patients died on the tenth day. Median hospitalization in SBDs was 10 days (Table 3).

Discussion

Our results demonstrate that quick improvements on the transthyretin and CRP level were observed in acute stroke patients who received leucine enriched BCAA dietary supplement added to baseline enteral nutrients.

Our patients were very elderly, suffered from impaired consciousness and renal dysfunction, and malnutrition within the 5 days of admission. We used EN containing leucine and MCT and provided protein of median 1.2 g or more (/kg/day) in the 29 patients [11]. Their TTR and Alb level, however, declined. Serum Cre acutely rose in two of the 25 patients administered with protein-rich EN, and protein-rich EN-induced deterioration of renal function, therefore, must be considered. We administered the LEBDs in the 15 patients, and 13 of them achieved an early discharge to comprehensive rehabilitation centers within 17 days after TTR and CRP were improving. Their clinical course was not usual. Thirteen of the 14 patients with SBDs survived and were transferred to comprehensive rehabilitation hospitals without improvements of TTR and CRP. SBDs might contribute to prevention of further deterioration of TTR, Alb and CRP, although SBDs could not improve them.

We supposed that the LEBDs had a quick effect on improvement of hypoproteinemia and cessation of inflammation in the 15 patients. After administration of the LEBDs, the TTR level rose soon, and the CRP level decreased soon, probably because leucine enriched BCAA played critical roles in the regulation of energy homeostasis, nutrition metabolism, gut health, immunity as they acted as potential anti-inflammatory mediators [26,27,28], further helped attenuate inflammation and enhance protein synthesis [13, 27, 28]. The Alb level did not change soon after the administration of the LEBDs, as the Alb level usually improves slowly. The LEBDs likely provides benefits with malnutrition patients in a stroke care unit or intensive care unit.

Study limitations

Our study had several limitations. Our study included a small number of patients. Our study was not a prospective randomized controlled study but a retrospective observational cohort study of routine medical care. We, therefore, did not have a placebo-controlled group without BCAA supplement, and we compared LEBDs group with SBDs group. The LEBDs contained MCT or n-3 fatty acids; no information, however, was provided in SBDs. Our patients started to use different types of enteral nutrients as the baseline. All patients were likely of Japanese ancestry; therefore, not representative of the general population. Our study investigated short-term outcomes of blood examinations, in-hospital death, and hospitalization days but did not study the long-term effect. To confirm our results, therefore, future prospective studies are required in patients with the standardization of enteral nutrients.

Conclusion

In acute stroke patients receiving leucine enriched BCAA dietary supplement, quick improvements in transthyretin and CRP were observed compared to patients with standard BCAA dietary supplement. The results warrant the further clinical application of the LEBDs in acute patients with malnutrition.

Availability of data and materials

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

Change history

  • 29 December 2020

    An amendment to this paper has been published and can be accessed via the original article.

Abbreviations

Alb:

Albumin

BCAA:

Branched-chain amino acid

BMI:

Body mass index

BW:

Body weight

Cre:

Creatinine

CRP:

C-reactive protein

eGFR:

estimated glomerular filtration rate

EN:

Enteral nutrient

ETF:

Enteral tube feeding

LEBDs:

Leucine enriched BCAA dietary supplement

SBDs:

Standard BCAA dietary supplement

TTR:

Transthyretin

References

  1. Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutrition Hospitalaria. 2005;20:38–45.

    CAS  Google Scholar 

  2. Fukushima K, Ueno Y, Kawagishi N, Kondo Y, Inoue J, Kakazu E, et al. The nutritional index ‘CONUT’ is useful for predicting long-term prognosis of patients with end-stage liver diseases. Tohoku J Exp Med. 2011;224:215–9.

    Article  Google Scholar 

  3. Zhang SQ, Peng B, Stary CM, Jian ZH, Xiong XX, Chen QX. Serum prealbumin as an effective prognostic indicator for determining clinical status and prognosis in patients with hemorrhagic stroke. Neural Regen Res. 2017;12:1097–102.

    Article  Google Scholar 

  4. Kamijo Y, Kanda E, Ishibashi Y, Yoshida M. Sarcopenia and frailty in PD: impact on mortality, malnutrition, and inflammation. Perit Dial Int. 2018;38:447–54.

    Article  CAS  Google Scholar 

  5. Izaola O, Gomez Hoyos E, Lopez JJ, Ortola A, Torres B, Primo D, et al. The 10-item eating assessment tool is associated with nutritional status, mortality and hospital stay in elderly individuals requiring hospitalization with acute diseases. Nutrition Hospitalaria. 2018;35:827–32.

    Google Scholar 

  6. Isono N, Imamura Y, Ohmura K, Ueda N, Kawabata S, Furuse M, et al. Transthyretin concentrations in acute stroke patients predict convalescent rehabilitation. J Stroke Cerebrovasc Dis. 2017;26:1375–82.

    Article  Google Scholar 

  7. Gao C, Zhang B, Zhang W, Pu S, Yin J, Gao Q. Serum prealbumin (transthyretin) predict good outcome in young patients with cerebral infarction. Clin Exp Med. 2011;11:49–54.

    Article  CAS  Google Scholar 

  8. Bourke CD, Berkley JA, Prendergast AJ. Immune dysfunction as a cause and consequence of malnutrition. Trends Immunol. 2016;37:386–98.

    Article  CAS  Google Scholar 

  9. Pellicane AJ, Millis SR, Barker KD, Temme KE, Sayyad A, Oswald MC, et al. The effect of protein and calorie intake on prealbumin, complications, length of stay, and function in the acute rehabilitation inpatient with stroke. NeuroRehabilitation. 2013;33:367–76.

    Article  Google Scholar 

  10. Mercier S, Breuille D, Mosoni L, Obled C, Patureau MP. Chronic inflammation alters protein metabolism in several organs of adult rats. J Nutr. 2002;132:1921–8.

    Article  CAS  Google Scholar 

  11. Morton RW, Traylor D, Weijs P, Phillips S. Defining anabolic resistance: implications for delivery of clinical care nutrition. Curr Opin Crit Care. 2018;24:124–30.

    Article  Google Scholar 

  12. Zhang S, Zeng X, Ren M, Mao X, Qiao S. Novel metabolic and physiological functions of branched chain amino acids: a review. J Animal Sci Biotechnol. 2017;8:10.

    Article  Google Scholar 

  13. Kato H, Miura K, Nakano S, Suzuki K, Bannai M, Inoue Y. Leucine-enriched essential amino acids attenuate inflammation in rat muscle and enhance muscle repair after eccentric contraction. Amino Acids. 2016;48:2145–55.

    Article  CAS  Google Scholar 

  14. Mori T, Tanno Y, Kasakura S, Yoshioka K, Nakai N, Oonuma Y. Impact of Leucine, Branched Chain Amino Acid, on Treating Malnutrition (O-026-6). In: The 43rd annual meeting of the Japan Stroke Society; 2018. March in Fukuoka.

    Google Scholar 

  15. Oonuma Y, Tanno Y, Chiba N, Mori T. Rapid improvement of malnutrition following treatment by leucine- enhanced branched chain amino acid in severe acute stroke patients fed with enteral nutrition. Stroke. 2019;50:ATP481.

    Article  Google Scholar 

  16. Kato H, Suzuki H, Mimura M, Inoue Y, Sugita M, Suzuki K, et al. Leucine-enriched essential amino acids attenuate muscle soreness and improve muscle protein synthesis after eccentric contractions in rats. Amino Acids. 2015;47:1193–201.

    Article  CAS  Google Scholar 

  17. Bukhari SS, Phillips BE, Wilkinson DJ, Limb MC, Rankin D, Mitchell WK, et al. Intake of low-dose leucine-rich essential amino acids stimulates muscle anabolism equivalently to bolus whey protein in older women at rest and after exercise. Am J Physiol Endocrinol Metab. 2015;308:E1056–65.

    Article  Google Scholar 

  18. Scherbakov N, Ebner N, Sandek A, Meisel A, Haeusler KG, von Haehling S, et al. Influence of essential amino acids on muscle mass and muscle strength in patients with cerebral stroke during early rehabilitation: protocol and rationale of a randomized clinical trial (AMINO-stroke study). BMC Neurol. 2016;16:10.

    Article  Google Scholar 

  19. Yoshimura Y, Bise T, Shimazu S, Tanoue M, Tomioka Y, Araki M, et al. Effects of a leucine-enriched amino acid supplement on muscle mass, muscle strength, and physical function in post-stroke patients with sarcopenia: a randomized controlled trial. Nutrition. 2019;58:1–6.

    Article  CAS  Google Scholar 

  20. Kudo D, Miyakoshi N, Hongo M, Kasukawa Y, Ishikawa Y, Mizutani T, et al. Relationship between preoperative serum rapid turnover proteins and early-stage surgical wound infection after spine surgery. Eur Spine J. 2017;26:3156–61.

    Article  Google Scholar 

  21. Long CL, Schaffel N, Geiger JW, Schiller WR, Blakemore WS. Metabolic response to injury and illness: estimation of energy and protein needs from indirect calorimetry and nitrogen balance. JPEN J Parenter Enteral Nutr. 1979;3:452–6.

    Article  CAS  Google Scholar 

  22. Ferard G, Gaudias J, Bourguignat A, Ingenbleek Y. C-reactive protein to transthyretin ratio for the early diagnosis and follow-up of postoperative infection. Clin Chem Lab Med. 2002;40:1334–8.

    Article  CAS  Google Scholar 

  23. Yang HT, Yim H, Cho YS, Kim D, Hur J, Kim JH, et al. Serum transthyretin level is associated with clinical severity rather than nutrition status in massively burned patients. JPEN J Parenter Enteral Nutr. 2014;38:966–72.

    Article  Google Scholar 

  24. Tsuboi A, Terazawa-Watanabe M, Kazumi T, Fukuo K. Associations of decreased serum transthyretin with elevated high-sensitivity CRP, serum copper and decreased hemoglobin in ambulatory elderly women. Asia Pac J Clin Nutr. 2015;24:83–9.

    CAS  PubMed  Google Scholar 

  25. Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet. 1974;304:81–4.

    Article  Google Scholar 

  26. Nie C, He T, Zhang W, Zhang G, Ma X. Branched chain amino acids: beyond nutrition metabolism. Int J Mol Sci. 2018;19:1–16.

    Article  Google Scholar 

  27. Nicastro H. Are the BCAAs/leucine supplementation effects on exercise-induced muscle damage related to HMβ? J Nutr Health Food Sci. 2014;2:1–3.

    Article  Google Scholar 

  28. Nicastro H, da Luz CR, Chaves DF, Bechara LR, Voltarelli VA, Rogero MM, et al. Does branched-chain amino acids supplementation modulate skeletal muscle remodeling through inflammation modulation? Possible mechanisms of action. J Nutr Metab. 2012;2012:1–10.

    Article  Google Scholar 

Download references

Acknowledgments

We would like to thank Nozomi Chiba, B.A., for her secretarial assistance, and the specialized assistance of the nurses and the nutritionists at our comprehensive stroke center.

Funding

The authors received no specific funding for this work.

Author information

Authors and Affiliations

  1. Department of Stroke Treatment, Shonan Kamakura General Hospital Stroke Center, Okamoto 1370-1, Kamakura City, Kanagawa, 247-8533, Japan

    Takahisa Mori & Kazuhiro Yoshioka

Authors
  1. Takahisa Mori
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Yoshioka
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Full access to all data in the study and responsibility for the integrity of the data and accuracy of the data analysis: TM. Study concept and design: TM. Patient treatment and care: TM, KY. Acquisition of data: TM, KY. Interpretation of data and statistical analysis: TM. Drafting the manuscript: TM. Critical revision of the manuscript for relevant intellectual content: TM. Final approval of the submitted version: TM, KY.

Corresponding author

Correspondence to Takahisa Mori.

Ethics declarations

Ethics approval and consent to participate

All procedures performed in the study were in accordance with the ethical standards of the institution (Shonan Kamakura General Hospital) and with the 1964 Helsinki Declaration. The Tokushukai Group Ethical Committee approved access to medical records for our retrospective analysis. Informed consent was not required because of routine medical care, the retrospective access to medical records in very elderly, disabled stroke patients treated four years ago, and the anonymization of patient identifiers.

Consent for publication

Not applicable.

Competing interests

The authors have no conflicts of interest to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mori, T., Yoshioka, K. Quick and effective improvement of leucine enriched dietary supplement on malnutrition in acute stroke patients receiving enteral tube feeding. BMC Emerg Med 20, 56 (2020). https://doi.org/10.1186/s12873-020-00351-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12873-020-00351-w

Keywords

BMC Emergency Medicine

ISSN: 1471-227X

Contact us